drugset / Trial / NCT01594255

CAEB071 Thorough QTc Study in Healthy Volunteers

NCT01594255

Phase 1 Completed 100 enrolled Novartis Pharmaceuticals
RandomizedCrossoverDouble-blindBasic science

Summary

This study has been designed in compliance with the ICH-E14 guideline 2005 to evaluate the QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs.

Timeline

Start
2009-07
Primary completion
2009-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule
Subject sotrastaurin Small molecule 300 mg
Subject sotrastaurin Small molecule 900 mg

Indications

No indication recorded.